Graft-versus-host disease (GVHD) is a serious, life-threatening complication that can arise after allogeneic stem cell transplantation. In recent years, a better understanding of the clinical science on GVHD pathology has led to the development of multiple novel targeted strategies for treatment of acute and chronic conditions. These include agents that inhibit T-cell activation by blocking the co-stimulatory pathway for prophylaxis of acute GVHD as well as those that inhibit signaling through JAK/STAT or BTK. The management landscape of GVHD is thus poised to make a leap into an era in which multiple effective options become available for acute and chronic disease, including in patients without any current guideline-recommended or approved regimens.

PeerView’s Live CME certified, lunch symposium will utilize the “CaseBook” format, offering learners a collection of patient stories from the experts’ personal repertoire paired with analyses of how the treatment landscape in GVHD is evolving. Hematology-oncology and bone marrow transplant professionals will take a deep dive into the underlying immunology of GVHD science and the latest evidence with innovative therapeutics while also obtaining expert perspectives on the practical application of these advancements as prophylaxis or for treatment of acute and chronic,
steroid-non-responsive, and previously untreated GVHD.

THREE KEY REASONS TO ATTEND

• Gain a better understanding of key concepts in GVHD pathophysiology
• Reduce the risk of severe acute GVHD in your transplant patients
• Get the latest update on innovative therapeutics, such as JAK1/2 and BTK inhibitors, for acute and chronic GVHD